Omeros Co. (NASDAQ:OMER) Given Consensus Rating of "Moderate Buy" by Brokerages

Omeros Co. (NASDAQ:OMER - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six brokerages that are covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $18.00.

OMER has been the topic of a number of recent analyst reports. D. Boral Capital restated a "buy" rating and set a $36.00 price target on shares of Omeros in a research note on Tuesday, May 13th. HC Wainwright initiated coverage on shares of Omeros in a research note on Tuesday, June 10th. They set a "buy" rating and a $9.00 price target on the stock. Wall Street Zen lowered shares of Omeros from a "hold" rating to a "sell" rating in a research note on Friday, June 6th. Finally, Needham & Company LLC restated a "hold" rating on shares of Omeros in a research note on Friday, May 16th.

Omeros Stock Down 4.2%

NASDAQ OMER opened at $3.40 on Monday. The firm has a market cap of $199.22 million, a PE ratio of -1.47 and a beta of 2.20. The company has a 50 day moving average price of $5.11 and a 200 day moving average price of $7.68. Omeros has a 52 week low of $2.97 and a 52 week high of $13.60.

Omeros (NASDAQ:OMER - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.05). On average, equities research analysts anticipate that Omeros will post -3.09 earnings per share for the current fiscal year.

Institutional Trading of Omeros

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Omeros by 3.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company's stock worth $314,000 after acquiring an additional 1,110 shares during the period. Truvestments Capital LLC increased its stake in shares of Omeros by 116.5% in the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 1,669 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Omeros by 79.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock worth $44,000 after acquiring an additional 1,972 shares during the period. Deutsche Bank AG increased its stake in shares of Omeros by 4.9% in the first quarter. Deutsche Bank AG now owns 42,019 shares of the biopharmaceutical company's stock worth $345,000 after acquiring an additional 1,973 shares during the period. Finally, Ameriprise Financial Inc. increased its stake in shares of Omeros by 2.0% in the fourth quarter. Ameriprise Financial Inc. now owns 120,493 shares of the biopharmaceutical company's stock worth $1,190,000 after acquiring an additional 2,317 shares during the period. Institutional investors and hedge funds own 48.79% of the company's stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.